xIPOmeter
BenevolentAI
BenevolentAI está a la vanguardia de la inteligencia artificial en el descubrimiento y desarrollo de fármacos. La plataforma de IA de la empresa analiza datos científicos para encontrar nuevas conexiones y perspectivas, acelerando el proceso de desarrollo de nuevas terapias.
Gráfico NewsHeat
- Semana
- Mes
- Año
- Noticias de prensa
- Noticias corporativas
Los datos del gráfico anterior se basan en datos derivados de nuestro modelo de cálculo XP patentado y pueden modificarse, ajustarse y actualizarse sin previo aviso.
Valoración de empresas
- Valoración
- Precio de las acciones
- Financiación acumulada
Los datos de los cuadros y gráficos se basan en datos de fuentes públicas y, aunque hacemos todo lo posible por recopilarlos, es posible que no coincidan con los datos reales del emisor.
Noticias relacionadas con BenevolentAI30
BenevolentAIBenevolentAI announces 3-year collaboration expansion with ...
The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify ...
https://www.streetinsider.com/Press+Releases/BenevolentAI+announces+3-year+collaboration+expansion+with+AstraZeneca+focused+on+systemic+lupus+erythematosus+and+heart+failure/19455518.htmlBenevolentAIPharmaceutical AI Platform and Software Global Market Insights ...
BenevolentAI. Atomwise. AI Therapeutics. Insilico Medicine. Recursion Pharmaceuticals. Lantern Pharma. Adaptive Biotechnologies....
https://uk.finance.yahoo.com/news/pharmaceutical-ai-platform-software-global-132100228.htmlBenevolentAIValneva: Chikungunya vaccine trial met primary endpoint after ...
Chikungunya is a viral disease transmitted to humans by infected mosquitoes and there is currently no vaccine or specific drug against the virus....
https://www.nasdaq.com/articles/valneva%3A-chikungunya-vaccine-trial-met-primary-endpoint-after-positive-phase-3-resultsBenevolentAIValneva says Chikungunya vaccine Phase 3 trial has met primary ...
Chikungunya is a viral disease transmitted to humans by infected mosquitoes that causes fever as well as muscle and joint pain....
https://www.nasdaq.com/articles/valneva-says-chikungunya-vaccine-phase-3-trial-has-met-primary-endpointBenevolentAIData hunters will be Big Pharma's next prey | Nasdaq
BenevolentAI uses artificial intelligence to accelerate drug discovery. - Drugmakers globally spend $160 billion on new research and development each year, ...
https://www.nasdaq.com/articles/data-hunters-will-be-big-pharmas-next-prey
Ver más (25)Inversores6
Goldman Sachs
Woodford Investment Management
Lundbeck
Upsher Smith Laboratories
Lansdowne Partners
Temasek Holdings